Comparing the current results to its competitors, Collplant Biotechnologies Ltd reported Revenue increase in the 4 quarter 2025 by 0 % year on year. The revenue growth was below Collplant Biotechnologies Ltd's competitors' average revenue growth of 3.67 %, achieved in the same quarter.
Collplant Biotechnologies Ltd, slower than the average decrease reported by the company's competitors of -19.86 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -19.86 %
Collplant Biotechnologies Ltd's Comment on Competition and Industry Peers
The company operates in the regenerative and aesthetic medicine fields, which are characterized by competition and rapid technological change. Its competitors include multinational pharmaceutical companies, biotechnology firms, medical technology companies, universities, and research institutions in the United States and internationally. Many of these competitors possess greater financial, technical, and other resources, as well as extensive marketing and sales operations. This competitive environment may affect the company's ability to commercialize its products.
August 19, 2024
In the fair city of Rehovot, Israel, alongside the industrious township of Eden Prairie, Minnesota, a novel alliance hath been forged between the esteemed firm CollPlant Biotechnologies and the venerable Stratasys Ltd. In a momentous declaration pronounced today, the two corporations have unveiled the initiation of a pre-clinical study heralding the development of commercial-sized breast implants, specifically fashioned through the art of bioprinting, utilizing the state-of-the-art Stratasys Origin 3D printer.This prodigious undertaking aims to advance the field of regenerative medicine, as the esteemed collaborators delve into the creation of 200cc breast implants that promise not only innovation but also a...
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
3M Company operates a diversified business model by offering innovative solutions across multiple segments, including healthcare, safety and industrial, transportation, and consumer goods. The company leverages its extensive portfolio of patents and deep customer relationships to drive product development and market responsiveness, focusing on delivering value across various industries.
Organogenesis Holdings Inc is a regenerative medicine company that specializes in the development and commercialization of advanced wound care and surgical biologic products. Their business model revolves around leveraging their expertise in tissue engineering and biotherapeutics to create innovative products aimed at treating various chronic and acute conditions. Through strategic partnerships, they distribute their products globally to healthcare professionals and patients in need, focusing on improving patient outcomes and quality of life.
Tanzanian Gold Corporation operates as a gold exploration and mining company in Tanzania. Its business model revolves around identifying and developing gold properties through various exploration methods, aiming to enhance shareholder value by efficiently extracting and selling gold resources.
Sources:
Collplant Biotechnologies Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Collplant Biotechnologies Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
